ArgusEye completes oversubscribed seed funding round

ArgusEye has successfully completed its first external financing round, securing additional funding for further product development and team expansion.

The strong investor syndicate in this oversubscribed funding round is led by Eir Ventures and ALMI Invest together with 10 life science experienced business angels. NY Consulting has provided strategic and financial advisory support during the fundraising process.

“We are thrilled and proud that such an esteemed group of investors want to support our journey and help us to bring our innovative sensor technology to the market. This capital injection will enable us to accelerate our product development, initiate our first product launch and expand the team. This is an important milestone for the company, and we are really looking forward to the upcoming scaling of our business and meeting biopharmaceutical industry demand,” says Erik Martinsson, Co-founder and CEO of ArgusEye.

Magnus Persson, Founding Partner at Eir Ventures states “We are very impressed with the team behind ArgusEye and see potential for substantial improvements in current biopharmaceutical production processes by applying the company´s innovative sensor technology. We are delighted to join and support the company as it works towards bringing its promising technology to the market”.


For more information please contact:
Erik Martinsson, CEO
erik.martinsson@arguseye.se